What Was Approved?
On August 28, 2026, the U.S. Food and Drug Administration approved Mimrylo (rusfertide) for adults with polycythemia vera, a rare blood disorder in which the body produces too many red blood cells.
The approval provides a new treatment option for patients whose disease has not been adequately controlled with existing therapy.
What Is Polycythemia Vera?
Polycythemia vera, often called PV, is a chronic blood disorder that causes excessive production of red blood cells.
When too many red blood cells are present, the blood can become more concentrated.
This may increase the risk of complications such as:
- Blood clots
- Stroke
- Heart attack
Managing the number of red blood cells is therefore an important part of treatment.
What Is Hematocrit?
Hematocrit is the percentage of blood made up of red blood cells.
In patients with polycythemia vera, a major treatment goal is generally to keep hematocrit below 45%.
If the hematocrit rises too high, some patients may need phlebotomy, a procedure in which blood is removed from a vein to lower the red blood cell level.
How Does Mimrylo Work?
Mimrylo is a hepcidin mimetic.
Hepcidin is a hormone involved in regulating iron availability in the body.
Because iron is needed to make red blood cells, Mimrylo limits the amount of iron available for new red blood cell production.
This mechanism is intended to help control excessive red blood cell production in polycythemia vera.
How Is Mimrylo Given?
In the phase 3 study supporting FDA approval, treatment began with 19 mg given by subcutaneous injection once weekly.
The dose was then adjusted as needed to help maintain hematocrit below 45%.
Patients should follow the dosing instructions in the FDA-approved prescribing information and from their healthcare professional.
What Did the Clinical Trial Show?
The FDA evaluated Mimrylo in the VERIFY trial, a randomized, double-blind, placebo-controlled phase 3 study involving 293 adults with polycythemia vera who continued to require frequent phlebotomy despite standard treatment.
The main effectiveness measure looked at whether patients avoided meeting criteria for phlebotomy during weeks 20 through 32.
According to the FDA:
- 76.9% of patients treated with Mimrylo required no phlebotomies during the study period.
- 32.9% of patients receiving placebo required no phlebotomies.
These results supported the FDA’s approval decision.
What Were the Most Common Side Effects?
The FDA reported that the most common adverse reactions were:
- Injection-site reactions
- Anemia
Patients may experience other adverse effects as well, and the complete FDA-approved prescribing information should be reviewed before treatment.
Does Mimrylo Replace All Other Polycythemia Vera Treatments?
Not necessarily.
Polycythemia vera treatment is individualized.
Depending on the patient, management may still involve approaches such as phlebotomy, medications that reduce blood-cell production, and other measures intended to reduce complications.
Mimrylo represents an additional treatment option rather than a treatment that automatically replaces every existing therapy.
Who Should Discuss Mimrylo With a Specialist?
Treatment decisions should be made with a hematology specialist.
Factors that may affect treatment decisions include:
- Current hematocrit levels
- Frequency of required phlebotomy
- Other medications
- History of blood clots
- Anemia or other blood abnormalities
- Other medical conditions
Why Is This Approval Important?
Mimrylo introduces a different treatment strategy for polycythemia vera.
Rather than directly removing blood or broadly suppressing blood-cell production, it targets iron availability through a hepcidin-like mechanism.
The FDA described Mimrylo as the first approved polycythemia vera treatment to mimic hepcidin.
Bottom Line
Mimrylo (rusfertide) is a newly FDA-approved treatment for adults with polycythemia vera.
It is administered by subcutaneous injection and works by limiting iron availability needed for excessive red blood cell production.
In the phase 3 VERIFY study, patients receiving Mimrylo were substantially more likely than those receiving placebo to avoid phlebotomy during the study’s key evaluation period.
Because polycythemia vera can carry serious cardiovascular and blood-clot risks, treatment and monitoring should be managed by an appropriate healthcare professional.
Sources
- U.S. Food and Drug Administration (FDA) — FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder, August 28, 2026.
- U.S. Food and Drug Administration (FDA) — FDA Newsroom, August 2026.